David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on CareRx. The associated price target remains the same with C$3.75.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
David Martin PhD has given his Buy rating due to a combination of factors that highlight CareRx’s strategic growth and operational improvements. The company has shown a positive trend in bed growth, with an increase in the average number of serviced beds during the second quarter of 2025, surpassing Bloom Burton’s estimates. This growth is attributed to strategic acquisitions, such as Southbridge’s acquisition of Revera, which added a significant number of beds to CareRx’s portfolio.
Moreover, the company’s decision to offboard less profitable contracts has streamlined operations, allowing for a more focused and profitable business model. The infrastructure improvements and the visibility for future acceleration in bed count further support the potential for continued growth. These factors collectively contribute to a positive outlook for CareRx, justifying the Buy rating.
Martin PhD covers the Healthcare sector, focusing on stocks such as Knight Therapeutics, CareRx, and Microbix Biosystms. According to TipRanks, Martin PhD has an average return of 16.6% and a 50.00% success rate on recommended stocks.